Investment Thesis
Xtant Medical is a growth-stage medical device company achieving strong 14.2% revenue growth and healthy 57.3% gross margins, but remains unprofitable with negative operating cash flow (-$2.1M) and is destroying shareholder value (ROE: -6.4%). While improving loss trajectory and low leverage provide runway, the company's inability to convert strong gross margins to operating profitability signals fundamental operational challenges that must be resolved.
Strengths
- Revenue growth of 14.2% YoY demonstrates market demand and expansion
- Gross margin of 57.3% indicates strong product/pricing power in medical devices
- Improving loss profile with net income improving 130.2% YoY toward breakeven
- Strong balance sheet with low debt-to-equity ratio of 0.17x and good liquidity ratios (current: 3.34x, quick: 1.64x)
- Total assets of $78M and stockholders equity of $48.6M provide adequate financial base
Risks
- Negative operating cash flow (-$2.1M) and free cash flow (-$2.3M) indicate the business is not self-sustaining
- Operating margin of -14% and net margin of -14.8% with negative ROE (-6.4%) and ROA (-4.0%) indicate value destruction
- Negative interest coverage ratio of -4.9x means operating losses prevent debt service from operations
- Cash runway of approximately 5 years at current burn rate with only $12.1M cash on hand
- Gap between strong gross margins and negative operating income suggests unresolved operational or cost structure issues
Key Metrics to Watch
- Operating cash flow trend toward positive territory (critical inflection point)
- Path to operating profitability and timeline to achieve positive net income
- Operating expense ratio as percentage of revenue (can they achieve operational leverage?)
- Cash burn rate and runway extension through profitability or capital raises
- Gross margin sustainability as company scales production
Financial Metrics
Revenue
20.9M
Net Income
-3.1M
EPS (Diluted)
$-0.02
Free Cash Flow
-2.3M
Total Assets
78.0M
Cash
12.1M
Profitability Ratios
Gross Margin
57.3%
Operating Margin
-14.0%
Net Margin
-14.8%
ROE
-6.4%
ROA
-4.0%
FCF Margin
-11.1%
Balance Sheet & Liquidity
Current Ratio
3.34x
Quick Ratio
1.64x
Debt/Equity
0.17x
Debt/Assets
37.7%
Interest Coverage
-4.88x
Long-term Debt
8.1M
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-14T07:43:16.641331 |
Data as of: 2026-03-31 |
Powered by Claude AI